Federal Policy Meets Clinical Innovation: A Conversation With ASTP/ONC is starting in

SULT4A1-1 Guided Antipsychotic Therapy Can Greatly Reduce Schizophrenia Hospitalization Costs

August 28, 2012
The study was conducted by SureGene, LLC, which develops and markets tests to facilitate personalized prescribing based on the presence or absence of genetic biomarkers associated with medication response or adverse events.  The report is based on an analysis of rehospitalization data from Caucasian patients participating in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study who consented to genotyping.
Download the Report
. . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.